Biotech firm takes personalized cancer therapy to phase I and appoints CMO

Danish Evaxion Biotech has dosed the first patient in a clinical phase I trial targeting three forms of cancer. The company develops personalized cancer immunotherapies via its artificial intelligence platform, and the market is worth millions of dollars, says the CEO.

Photo: Evaxion Biotech

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles